Lanreotide: Uses, Mechanism, and Side Effects

Patients managing acromegaly or certain neuroendocrine tumors often want to understand how their treatment works and what to expect. Lanreotide is a long-established injectable therapy with a defined role across several hormone-related conditions.

Key takeaways

• Lanreotide is a somatostatin analog marketed as Lanreotide Acetate.
• It is approved for acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome.
• More than 125 registered trials have studied lanreotide, including combination regimens with other cancer therapies.
• FAERS reports most commonly include diarrhea, fatigue, nausea, and injection site pain, alongside off-label use reports.
• The drug does not carry a boxed warning.

What Lanreotide Is

Lanreotide is an octapeptide analog of natural somatostatin, a hormone that regulates the release of several other hormones in the body. Its mechanism of action is believed to mirror that of natural somatostatin, which generally works by suppressing excess hormone secretion. This action underlies its use in conditions marked by hormone overproduction, such as acromegaly and hormone-secreting tumors.

What Lanreotide Is Approved For

Lanreotide is indicated for the long-term treatment of acromegaly in patients who have had an inadequate response to, or cannot undergo, surgery and radiotherapy. It is also approved for adults with unresectable, well- or moderately-differentiated, locally advanced or metastatic GEP-NETs, where it is used to improve progression-free survival. A third approved use is for adults with carcinoid syndrome, where lanreotide reduces the frequency of needing short-acting somatostatin analog rescue therapy. The label lists Lanreotide Acetate as the marketed brand name.

What The Evidence Shows

Lanreotide has been studied in more than 125 registered clinical trials. One completed Phase 2 trial evaluated lanreotide autogel combined with temozolomide in patients with thoracic neuroendocrine tumors. A separate Phase 2 trial, with an unknown current status, examined lanreotide combined with cabozantinib in patients with GEP-NETs. Other research has looked at switching patients from octreotide, a related somatostatin analog, to lanreotide.

Reported Side Effects

Reports submitted to FAERS reflect adverse event counts, not confirmed incidence or proven causation. The most frequently reported reactions involve gastrointestinal and general symptoms: diarrhea (1,415 reports), fatigue (972), nausea (725), and abdominal pain (568). Injection site pain (596 reports) and headache (502) are also commonly noted. Reports of death (1,221) and off-label use (1,461) appear among the most frequent entries, reflecting the broad population and settings in which the drug is used.